Preventive HIV vaccine clinical trials are happening in communities across America.
Don't see your city listed above?
Find out how you can help
Enter your email address in the field below to receive important updates from Be the Generation.
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced today that the prime-boost investigational vaccine regimen was safe and 31 percent effective in preventing HIV infection. Read more.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has opened enrollment in HVTN 505, an exploratory HIV vaccine clinical study examining whether a two-part vaccine regimen can decrease viral load (the amount of HIV in the blood) in study participants who later become infected with HIV. Viral load is an important health indicator in people who are infected with HIV because typically those with less virus remain healthier longer. Further, HIV-infected individuals with reduced levels of virus may be less likely to transmit the virus to other people. Read more.
Comments or questions? Email us.